JohnSPollackMD

Retinal Disease

Partner, Illinois Retina Associates; Asst. Prof. Ophthalmology, Rush University Medical Center; Chief Medical Officer, jCyte

Join to view full profile

Dr. Pollack is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Pollack's full profile

Already have an account?

Office
12 Salt Creek Lane, Suite 110
Hinsdale, IL 60521
Is this information wrong?

Education & Training

Medical College of WisconsinFellowship, Vitreoretinal Surgery, 1995 - 1997
Washington University/B-JH/SLCH ConsortiumResidency, Ophthalmology, 1992 - 1995
Washington University/B-JH/SLCH ConsortiumInternship, Internal Medicine, 1991 - 1992
Georgetown University School of MedicineClass of 1991

Certifications & Licensure

IL State Medical License 1997 - 2026
MO State Medical License 1992 - 2015
WI State Medical License 1995 - 2009
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

Retina Hall of Fame – Charter Inductee Retina Hall of Fame, 2017
OSN Retina 150 Innovators in Medical and Surgical Retina OSN Retina, 2015
American Academy of Ophthalmology "Achievement Award" American Academy of Ophthalmology, 2010
American Society of Retina Specialists "Senior Honor Award" American Society of Retina Specialists, 2001
Join now to see all

Clinical Trials

A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin) Start of enrollment: 2006 Jun 01
Completed
Phase 2
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial Start of enrollment: 2008 Feb 01
Completed
Phase 3
Patient Assessment of Topical Anesthetic Effectiveness for Intravitreal Injections Start of enrollment: 2009 Oct 01
Completed
Phase 3
Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study Start of enrollment: 2010 Feb 01
Completed
Phase 2
Phase II Combination Steroid and Anti-VEGF for Persistent DME Start of enrollment: 2014 Feb 01
Completed
Phase 2
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Start of enrollment: 2014 Sep 01
Completed
Phase 3
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration Start of enrollment: 2015 Sep 28
Completed
Phase 2
A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration Start of enrollment: 2018 Sep 12
Completed
Phase 3
Extension Study for the Port Delivery System With Ranibizumab (Portal) Start of enrollment: 2018 Sep 20
Recruiting
Phase 3
This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab Start of enrollment: 2019 Sep 30
Active, not recruiting
Phase 3
The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy Start of enrollment: 2019 Nov 15
Completed
Phase 3
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm Start of enrollment: 2020 Aug 10
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

9 citations
Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema: Clinical Outc...
Thomas A Ciulla, Rehan M Hussain, Donna Taraborelli, John S Pollack, David F Williams> ;Ophthalmology. Retina. 2022 Sep 1
72 citations
Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes
Thomas A. Ciulla, John S. Pollack, David F. Williams> ;The British Journal of Ophthalmology. 2021 Feb 1
2 citations
Development, Validation, and Innovation in Ophthalmic Laser-Based Imaging: Report From a US Food and Drug Administration-Cosponsored Forum.
Frank L. Brodie, Michael X. Repka, Stephen A. Burns, S. Grace Prakalapakorn, Christie L. Morse, Joel S. Schuman, Michael R. Dueñas, Natalie A. Afshari, John S. Pollack...> ;JAMA Ophthalmology. 2021 Jan 1
Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema.
Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H, Diabetic Retino...> ;Ophthalmology.
Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment.
Do DV, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, Sophie R, Hafiz G, Campochiaro PA, READ-2 Study Group> ;JAMA ophthalmology.
Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial.
Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, Grover S, Miller DG, Diabetic Retinopathy Clinical Research Network> ;JAMA ophthalmology.
VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (...
Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF, Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group> ;JAMA ophthalmology.
Topical nepafenec in eyes with noncentral diabetic macular edema.
Friedman SM, Almukhtar TH, Baker CW, Glassman AR, Elman MJ, Bressler NM, Maker MP, Jampol LM, Melia M, Diabetic Retinopathy Clinical Research Network> ;Retina (Philadelphia, Pa.).
Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive...
Bressler SB, Almukhtar T, Bhorade A, Bressler NM, Glassman AR, Huang SS, Jampol LM, Kim JE, Melia M, Diabetic Retinopathy Clinical Research Network Investigators> ;JAMA ophthalmology.
15 citations
Baseline Visual Acuity at Wet AMD Diagnosis Predicts Long-Term Vision Outcomes: An Analysis of the IRIS Registry
Allen C. Ho, David M. Kleinman, Flora Lum, Jeffrey S. Heier, Richard L. Lindstrom, Susan C Orr, Grace C Chang, Eleanor L Smith, John S. Pollack> ;Ophthalmic Surgery, Lasers & Imaging Retina. 2020 Nov 1
22 citations
Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes.
Thomas A. Ciulla, John S. Pollack, David F. Williams> ;The British Journal of Ophthalmology. 2020 Oct 14
92 citations
Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of...
Thomas A. Ciulla, Rehan M. Hussain, John S. Pollack, David F. Williams> ;Ophthalmology. Retina. 2020 Jan 1
10 citations
Small gauge vitrectomy: operative techniques.
John S. Pollack, Naryan Singh Sabherwal> ;Current Opinion in Ophthalmology. 2019 May 1
90 citations
Real-world Outcomes of Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema in the United States
Thomas A. Ciulla, Peter Bracha, John S. Pollack, David F. Williams> ;Ophthalmology. Retina. 2018 Jul 29
27 citations
Twenty-four–Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes – Protocol 3 with High Dose (READ-3) Study
Yasir J. Sepah, Mohammad Ali Sadiq, David S. Boyer, David Callanan, Ron P. Gallemore, Michael Bennett, Dennis M. Marcus, Lawrence Halperin, Muhammad Hassan, Peter A. C...> ;Ophthalmology. 2016 Dec 1
77 citations
Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice
Jeffrey S. Heier, Neil M. Bressler, Robert L. Avery, Sophie J. Bakri, David S. Boyer, David Brown, Pravin U. Dugel, K. Bailey Freund, Adam R. Glassman, Judy E. Kim, Da...> ;JAMA Ophthalmology. 2016 Jan 1
124 citations
Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials
Alex S. Willoughby, Gui-Shuang Ying, Cynthia A. Toth, Maureen G. Maguire, Russell Burns, Juan E. Grunwald, Ebenezer Daniel, Glenn J. Jaffe, David F. Williams, Sara Bea...> ;Ophthalmology. 2015 Sep 1
Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).
Altaweel MM, Daniel E, Martin DF, Mittra RA, Grunwald JE, Lai MM, Melamud A, Morse LS, Huang J, Ferris FL, Fine SL, Maguire MG, Comparison of Age-related Macular Degen...> ;Ophthalmology. 2014-10-11
Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials.
Folgar FA, Jaffe GJ, Ying GS, Maguire MG, Toth CA, Comparison of Age-Related Macular Degeneration Treatments Trials Research Group> ;Ophthalmology. 2014-05-15
1 citations
The value of healthcare data in ophthalmology.
Nicholas G. Anderson, John S. Pollack, David Williams> ;Current Opinion in Ophthalmology. 2014 May 1
Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
Kim BJ, Ying GS, Huang J, Levy NE, Maguire MG, CATT Research Group> ;American journal of ophthalmology. 2014-04-13
Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab.
Channa R, Sophie R, Khwaja AA, Do DV, Hafiz G, Nguyen QD, Campochiaro PA, READ-2 Study Group> ;Eye (London, England). 2013-11-22
Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.
Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, Grunwald JE, Huang J, Comparison of Age-related Macular Degeneration Treatments Trials Research Group> ;Ophthalmology. 2013-05-01
Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.
Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF, Comparison of Age-related Macular Degeneration Treatme...> ;Ophthalmology. 2012-10-06
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford...> ;Ophthalmology. 2012-05-01
Join now to see all

Press Mentions

Big Data, Analytics, and AI in Retina PracticeNovember 1st, 2019
REGENXBIO Reports Continued Progress Across Programs in Year-End 2018 Corporate UpdateJanuary 3rd, 2019
Tributes to a Legend in Retina: Kirk Packo, MD, FACSOctober 3rd, 2023